Clinical trial
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in…
NCT00124813 · University Hospital, Bonn, Other · Unknown status
Key facts
| NCT number | NCT00124813 |
|---|---|
| Title | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma |
| Official title | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma |
| Lead sponsor | University Hospital, Bonn, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | thalidomide, idarubicin |
| Enrollment | 80 |
| Start date | Aug 1, 2002 |
| Primary completion | May 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Jul 28, 2005 |
| Last update posted | Feb 2, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: